Term
| calcium carbonate requrieemnt |
|
Definition
| needs antacid, stomach acid digestionbefore absorption. |
|
|
Term
| calcium citrate method of admin |
|
Definition
| orally, no digestion needed before digestion |
|
|
Term
calcium chloride method of admin
use:
complciations: |
|
Definition
Method fo admin: IV
use:hypocalcemia tetany
complication: vasodilation, vein irritation. |
|
|
Term
|
Definition
| for severe symptoamtic hypocalcemia, less vein irritation. |
|
|
Term
| calcium adverse toxicities |
|
Definition
| hypercalcemia, ectopic calcificaiton, pth suprression. |
|
|
Term
|
Definition
| itnerefere with thryoid hromoen rpelacement treatment |
|
|
Term
|
Definition
| calcimemtic, binds to CaR and increases senstiivity to calcium |
|
|
Term
|
Definition
| PTH release is inhibited.- useful in secodnary hyperPTH. |
|
|
Term
|
Definition
| secodnary hyerpparahtyrodiism due to chornic kdiney disease to control hyeprcalcemia |
|
|
Term
| side effect of cinacalcet |
|
Definition
| hypocalcemia and nausea (does not act liek aclcium peripehrally) |
|
|
Term
|
Definition
| most active form of vit D. (1,25 dihydroxyvitaminD) |
|
|
Term
|
Definition
|
|
Term
| calcitriol vs. cholcalciferol clerance |
|
Definition
| calcitriol- water soluble, cholecalciferol - fat soluble, cleared muchs lower. |
|
|
Term
|
Definition
| 1a hydroyvtiamin D2. only needs liver activation |
|
|
Term
|
Definition
| vitamin D2, ianctive prodrug, also fat solub.e |
|
|
Term
|
Definition
| 190 nor 1,25 dihydroxyviatmian D2 |
|
|
Term
| vitamin D supplement interaction |
|
Definition
| may incraseboen rpstion and decrease efficacy fo bipshopsohantes- calcium and vit D shoudl nto e reoccmended with bisphos administration |
|
|
Term
|
Definition
| for 2ndary hyperparahtyroidism due to CRF |
|
|
Term
|
Definition
| binds the VDR, directly supresses PTh gene without s timautling itnestinal clciu mor phosrphorus absorption |
|
|
Term
| adverse effects of Vitamind analogs |
|
Definition
| vitamin D intox, and hyeprcalcemia |
|
|
Term
|
Definition
| bisphosphnates- anti-bone catabolic agents. |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| first lien bisophospnhate |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| analog ofpyrophoaphate with a nonhdyrolyzable PCP bond, that accumualtes at bone ,preventing bone disoslution |
|
|
Term
| bisphosphonate mehcanistic effects |
|
Definition
preents differnaetion of macrophages into osteocalsts, inhibits osteclasts acitivty adn cause apoptosis.
inhbiits farnesyl pyrophposphate synthase- inhbiitng osteocalst actiity
anticancer activity. |
|
|
Term
| farnesyl pyrophosphate ysnthase |
|
Definition
|
|
Term
|
Definition
| osteoperosis, pagets disease of bone |
|
|
Term
|
Definition
| osteoperosis, pagets disease |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| bisphosphoantes idnicated for pagets |
|
Definition
| alednronate, risedronate, and pamidronate. |
|
|
Term
| realtive potency of bisphospnates |
|
Definition
| zoledronic acid>risedronate>ibadnroante>alendronate>pamidronate |
|
|
Term
|
Definition
reduciton in mienralization resulting in osteomalacia.
GI distress, hypocalcemia, and ulcerative esophagitis.
renal toxicity (excreted by kdineys).
Osteocnrosis foht e JAw.
Musculketlal pain.
Atypical Subtrochanteric Diaphyseal femoral fractures. |
|
|
Term
| Bisphosphante contranidncaitons |
|
Definition
| hypocalcemia, GI disease, esophageal abnormaliteis, kdiney disse, pregnancy |
|
|
Term
|
Definition
|
|
Term
|
Definition
| reduces serum calcium and phosphorus by increasing bone deposition and stimualting renal eceretion. PRoduced by paraficullicluar c cellcs of thryoid |
|
|
Term
| salmon calcointon vs. human |
|
Definition
| longerh alflife, clearedl ess |
|
|
Term
|
Definition
| pagets disease, increse bone density and reduce acute pain due to fractures. also soteoperosis |
|
|
Term
| caltinon advers e effects |
|
Definition
| tolerance-downregulation of calcitonin receptors, worsening of hotflashes |
|
|
Term
|
Definition
| anabolic agnet (fragment of PTH), used for osteoprorsis, reserved for patients at high risk for fracture. |
|
|
Term
|
Definition
| pth basically. hronic pth causes decrease in bone denisty. butintermiettent icreases in pth increse bone density. additionaly teriparatide is thoughtto bind to pth-R on osteoblasts but not on osteocalsts. |
|
|
Term
| adverse effects teriparatide |
|
Definition
| increased osteosarcoma isncidence |
|
|
Term
| contraindicaitons for teriparatide |
|
Definition
| increse baeline risk of osteocaroam,, or other metabolic diease of bone. |
|
|
Term
|
Definition
| monoclonal Abagainst RankL |
|
|
Term
|
Definition
| used in bone metasteses, can als obe used in osteoprorosis at high risk for fractures |
|
|
Term
|
Definition
| hypocalcemia, serious infections. |
|
|
Term
|
Definition
| can be usefu l in patients with hyeprcalciuria |
|
|
